United States · FDA National Drug Code directory
Darifenacin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 16571-767_fd55c56a-79a8-4830-92d7-19f62bee0b5f
- Product NDC
- 16571-767
- Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Composition / generic term
- Darifenacin
- Labeler
- Rising Pharma Holdings, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20160919
- Source listing expiry
- 20261231
Source-listed ingredients
- DARIFENACIN HYDROBROMIDE — 7.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16571-767-03) · 16571-767-03
- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (16571-767-09) · 16571-767-09
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →